SynAct Pharma AB (DE:8F8)
FRANKFURT:8F8
Want to see DE:8F8 full AI Analyst Report?
Total Valuation
SynAct Pharma AB has a market cap or net worth of €71.30M. The enterprise value is €695.02M.
Market Cap€71.30M
Enterprise Value€695.02M
Share Statistics
SynAct Pharma AB has 53,330,242 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,330,242
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
SynAct Pharma AB’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -54.66%.
Return on Equity (ROE)-0.65
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-54.66%
Return on Capital Employed (ROCE)-0.59
Revenue Per Employee0.00
Profits Per Employee-19.42M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of SynAct Pharma AB is ―. SynAct Pharma AB’s PEG ratio is -2.41.
PE Ratio―
PS Ratio0.00
PB Ratio6.78
Price to Fair Value6.78
Price to FCF-11.86
Price to Operating Cash Flow-41.88
PEG Ratio-2.41
Income Statement
In the last 12 months, SynAct Pharma AB had revenue of 0.00 and earned -110.83M in profits. Earnings per share was -2.17.
Revenue0.00
Gross Profit0.00
Operating Income-117.15M
Pretax Income-118.99M
Net Income-110.83M
EBITDA-117.15M
Earnings Per Share (EPS)-2.17
Cash Flow
In the last 12 months, operating cash flow was -41.90M and capital expenditures 0.00, giving a free cash flow of -41.90M billion.
Operating Cash Flow-41.90M
Free Cash Flow-41.90M
Free Cash Flow per Share-0.79
Dividends & Yields
SynAct Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change-18.90%
50-Day Moving Average1.55
200-Day Moving Average1.78
Relative Strength Index (RSI)33.91
Average Volume (3m)89.00
Important Dates
SynAct Pharma AB upcoming earnings date is May 27, 2026, TBA (Confirmed).
Last Earnings DateFeb 18, 2026
Next Earnings DateMay 27, 2026
Ex-Dividend Date―
Financial Position
SynAct Pharma AB as a current ratio of 3.31, with Debt / Equity ratio of 1.06%
Current Ratio3.31
Quick Ratio3.31
Debt to Market Cap<0.01
Net Debt to EBITDA0.44
Interest Coverage Ratio-47.80
Taxes
In the past 12 months, SynAct Pharma AB has paid -8.16M in taxes.
Income Tax-8.16M
Effective Tax Rate0.07
Enterprise Valuation
SynAct Pharma AB EV to EBITDA ratio is -9.41, with an EV/FCF ratio of -11.33.
EV to Sales0.00
EV to EBITDA-9.41
EV to Free Cash Flow-11.33
EV to Operating Cash Flow-11.33
Balance Sheet
SynAct Pharma AB has €68.89M in cash and marketable securities with €1.54M in debt, giving a net cash position of €67.35M billion.
Cash & Marketable Securities€68.89M
Total Debt€1.54M
Net Cash€67.35M
Net Cash Per Share€1.26
Tangible Book Value Per Share€0.44
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for SynAct Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-7.09%